IDYA:NSD-Ideaya Biosciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 41

Change

+0.68 (+1.69)%

Market Cap

USD 3.16B

Volume

1.51M

Analyst Target

USD 24.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.70 (+0.35%)

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

+9.97 (+0.97%)

USD 110.51B
MRNA Moderna Inc

-5.20 (-3.58%)

USD 57.87B
BNTX BioNTech SE

-3.92 (-4.08%)

USD 24.18B
ARGX argenx NV ADR

-1.34 (-0.35%)

USD 23.09B
ALNY Alnylam Pharmaceuticals Inc

+0.34 (+0.21%)

USD 20.25B
GMAB Genmab AS

-0.22 (-0.83%)

USD 18.17B
BGNE BeiGene Ltd

-3.80 (-2.28%)

USD 17.74B
RPRX Royalty Pharma Plc

-0.28 (-1.03%)

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

-0.73 (-0.87%)

USD 15.32B

ETFs Containing IDYA

IWC iShares Micro-Cap ETF 0.63 % 0.60 %

-2.22 (-1.93%)

USD 0.82B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.23% 68% D+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.23% 68% D+ 78% C+
Trailing 12 Months  
Capital Gain 87.21% 90% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 87.21% 90% A- 93% A
Trailing 5 Years  
Capital Gain 266.40% 93% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 266.40% 93% A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 70.59% 89% A- 93% A
Dividend Return 70.59% 89% A- 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 99.27% 26% F 16% F
Risk Adjusted Return 71.11% 98% N/A 90% A-
Market Capitalization 3.16B 93% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector